BIND Therapeutics Names Jonathan Yingling Chief Scientific Officer

(RTTNews) - BIND Therapeutics, Inc. (BIND) Wednesday announced the appointment of Jonathan Yingling, Ph.D., as Chief Scientific Officer. BIND is engaged in developing targeted and programmable therapeutics called ACCURINS.

Yingling will be responsible for leading BIND's research and development efforts to identify and pursue new product opportunities where the attributes of ACCURINs can be leveraged to provide meaningful improvements in patient care.

Yingling began his pharmaceutical career as a senior biologist in oncology at Eli Lilly & Company in 2000. During his 13-year tenure, he served in various positions of increasing responsibility.